Looking at the filing, I can see this is a Form 10-Q for Milestone Pharmaceuticals Inc. for the quarterly period ended September 30, 2026, filed on November 13, 2026. The ticker is MIST on The Nasdaq Stock Market LLC. Let me extract the key facts available in the provided text and produce the article.

Milestone Pharmaceuticals Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission, reporting 124,498,693 common shares outstanding as of November 13, 2026.

Key Highlights

  • Shares outstanding: As of November 13, 2026, Milestone Pharmaceuticals had 124,498,693 common shares, no par value per share, outstanding.
  • Filer classification: The company is classified as a non-accelerated filer and a smaller reporting company, and is not an emerging growth company.
  • Commercial product: According to the filing, the company is commercializing CARDAMYST (etripamil) nasal spray, approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
  • Development pipeline: The filing references a Phase 3 clinical trial of etripamil for the treatment of atrial fibrillation and rapid ventricular rate.
  • Licensing partnership: The filing discloses a license agreement with Everest Medicines, formerly partnered with Corxel Pharmaceuticals, covering commercialization of etripamil in China and development in Hong Kong, Macau, and Taiwan.
  • Cost measures: The filing references "recently implemented cost-efficiency measures intended to extend our cash runway," according to the company's forward-looking disclosures.

Milestone Pharmaceuticals: CARDAMYST Commercialization and Q3 2026 Disclosures

Milestone Pharmaceuticals Inc. (NASDAQ:MIST), a Québec-incorporated specialty pharmaceutical company headquartered at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montréal, Québec, filed its quarterly report covering the period ended September 30, 2026. The filing carries Commission File Number 001-38899. The company is not a shell company, according to the filing's check-mark disclosures.

The filing identifies CARDAMYST (etripamil) nasal spray as the company's commercial product, indicated for the conversion of acute symptomatic episodes of PSVT to sinus rhythm in adults. Beyond the approved indication, the filing states that the company is conducting a Phase 3 clinical trial of etripamil for atrial fibrillation and rapid ventricular rate, and that it retains plans to develop and commercialize additional product candidates, subject to regulatory approval.

Milestone Pharmaceuticals disclosed a license agreement with Everest Medicines, the successor partner formerly known as Corxel Pharmaceuticals, covering the potential commercialization of etripamil in China and development rights in Hong Kong, Macau, and Taiwan. The filing also notes that the company has implemented cost-efficiency measures intended to extend its cash runway, and that it is monitoring its ability to maintain compliance with Nasdaq Global Select Market continued listing standards. The company's forward-looking statements are subject to the risks and uncertainties described in the filing and in the company's Annual Report on Form 10-K filed with the SEC and under Milestone's SEDAR+ profile on March 20, 2026.

What Was Disclosed

Milestone Pharmaceuticals Inc. submitted a Form 10-Q for the quarter ended September 30, 2026, disclosing 124,498,693 common shares outstanding, its CARDAMYST commercial product status, an ongoing Phase 3 trial, a licensing partnership with Everest Medicines, and recently implemented cost-efficiency measures.